Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2019 3
2020 5
2021 1
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
Hager KJ, Pérez Marc G, Gobeil P, Diaz RS, Heizer G, Llapur C, Makarkov AI, Vasconcellos E, Pillet S, Riera F, Saxena P, Geller Wolff P, Bhutada K, Wallace G, Aazami H, Jones CE, Polack FP, Ferrara L, Atkins J, Boulay I, Dhaliwall J, Charland N, Couture MMJ, Jiang-Wright J, Landry N, Lapointe S, Lorin A, Mahmood A, Moulton LH, Pahmer E, Parent J, Séguin A, Tran L, Breuer T, Ceregido MA, Koutsoukos M, Roman F, Namba J, D'Aoust MA, Trepanier S, Kimura Y, Ward BJ; CoVLP Study Team. Hager KJ, et al. Among authors: ceregido ma. N Engl J Med. 2022 Jun 2;386(22):2084-2096. doi: 10.1056/NEJMoa2201300. Epub 2022 May 4. N Engl J Med. 2022. PMID: 35507508 Free PMC article. Clinical Trial.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. de Bruyn G, et al. Among authors: ceregido ma. EClinicalMedicine. 2023 Jul 22;62:102109. doi: 10.1016/j.eclinm.2023.102109. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37533419 Free PMC article.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 Study Team. Dayan GH, et al. Among authors: ceregido ma. Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13. Lancet Respir Med. 2023. PMID: 37716365 Clinical Trial.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kaali S, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Uchiyama A, Sawe F, Schuerman L, Shrestha R, Tong T, Treanor J, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 study team. Dayan GH, et al. Among authors: ceregido ma. EClinicalMedicine. 2023 Sep 12;64:102168. doi: 10.1016/j.eclinm.2023.102168. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37936652 Free PMC article.
Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.
Tseng HF, Sy LS, Ackerson BK, Lee GS, Luo Y, Florea A, Becerra-Culqui T, Tartof SY, Tian Y, Taylor C, Campora L, Ceregido MA, Kuznetsova A, Poirrier JE, Rosillon D, Valdes L, Cheuvart B, Mesaros N, Meyer N, Guignard A, Qian L. Tseng HF, et al. Among authors: ceregido ma. Vaccine. 2022 Jul 30;40(32):4503-4512. doi: 10.1016/j.vaccine.2022.06.009. Epub 2022 Jun 16. Vaccine. 2022. PMID: 35717267 Free article.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T, Bonaparte MI, Ceregido MA, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 study team. Dayan GH, et al. Among authors: ceregido ma. medRxiv [Preprint]. 2023 Jan 13:2022.12.05.22282933. doi: 10.1101/2022.12.05.22282933. medRxiv. 2023. PMID: 36523415 Free PMC article. Preprint.
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.
Charland N, Gobeil P, Pillet S, Boulay I, Séguin A, Makarkov A, Heizer G, Bhutada K, Mahmood A, Trépanier S, Hager K, Jiang-Wright J, Atkins J, Saxena P, Cheng MP, Vinh DC, Boutet P, Roman F, Van Der Most R, Ceregido MA, Dionne M, Tellier G, Gauthier JS, Essink B, Libman M, Haffizulla J, Fréchette A, D'Aoust MA, Landry N, Ward BJ. Charland N, et al. Among authors: ceregido ma. NPJ Vaccines. 2022 Nov 9;7(1):142. doi: 10.1038/s41541-022-00561-2. NPJ Vaccines. 2022. PMID: 36351931 Free PMC article.
21 results